Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 310 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mesenchymal Stem Cell Clear all
Not listed Phase 1Phase 2 Interventional

Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction

NCT03678467
View directory record Official record
Conditions
Mandible Tumor, Mandibular Injuries, Mandible; Deformity
Interventions
EB-CMF
Combination Product
Lead sponsor
Epibone, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
San Francisco, California • Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 10, 2026, 10:48 PM EDT
Not listed Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

NCT02833792
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Human Mesenchymal Stem Cells and Lactated Riunger's Solution, Placebo
Drug · Other
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 10, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis

NCT01933802
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
intrathecal administration of autologous MSC-NP
Biological
Lead sponsor
Tisch Multiple Sclerosis Research Center of New York
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 10, 2026, 10:48 PM EDT
Available No phase listed Expanded access

Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury

NCT07164482
View directory record Official record
Conditions
Brain Injury
Interventions
HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
14 Years to 78 Years
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 10, 2026, 10:48 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

NCT00562497
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 10, 2026, 10:48 PM EDT
Suspended Not applicable Interventional

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

NCT04064879
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
AD-SVF
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 10, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

NCT07512362
View directory record Official record
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
Interventions
human Mesenchymal Stem Cells
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
55 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 10, 2026, 10:48 PM EDT
Completed Early Phase 1 Interventional

Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation

NCT02468492
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Platelet Rich Plasma, Normal Saline
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 10, 2026, 10:48 PM EDT
Terminated Phase 1 Interventional

Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)

NCT02013700
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs), matched placebo
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
40 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 10, 2026, 10:48 PM EDT
Completed Phase 3 Interventional

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

NCT01233960
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prochymal®
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
San Francisco, California • Clearwater, Florida • Winter Park, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 10, 2026, 10:48 PM EDT
Not listed Phase 2 Interventional

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

NCT04905836
View directory record Official record
Conditions
Covid19
Interventions
COVI-MSC, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Brandon, Florida • Sarasota, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 10, 2026, 10:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial

NCT04652908
View directory record Official record
Conditions
Myelomeningocele
Interventions
Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix, Untreated contemporaneous cohort
Biological · Other
Lead sponsor
University of California, Davis
Other
Eligibility
19 Weeks to 25 Weeks
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 10, 2026, 10:48 PM EDT
Terminated Phase 1 Interventional

Mesenchymal Stem Cells in Early Rheumatoid Arthritis

NCT03186417
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
2 million hMSC/kg, 4 million hMSC/kg, 6 million hMSC/kg, placebo
Biological
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 10, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cells (MSC) for Ovarian Cancer

NCT02530047
View directory record Official record
Conditions
Ovarian Cancer
Interventions
MSC-INFβ, Questionnaires
Genetic · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 10, 2026, 10:48 PM EDT
Not listed Early Phase 1 Interventional

Micro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury

NCT03167138
View directory record Official record
Conditions
Shoulder Pain, Shoulder Impingement Syndrome, Rotator Cuff Impingement Syndrome, Rotator Cuff Tendinitis, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Spinal Cord Injuries
Interventions
Autologous micro-fragmented adipose tissue, Lipogems system
Biological · Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 10, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.

NCT04348435
View directory record Official record
Conditions
COVID-19
Interventions
HB-adMSCs, Placebos
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 10, 2026, 10:48 PM EDT
Recruiting Phase 1 Interventional

AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses

NCT04392206
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Adipose Derived Mesenchymal Stem Cells
Drug
Lead sponsor
Houssam Farres, M.D.
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 10, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

NCT03929120
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Diseases
Interventions
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 10, 2026, 10:48 PM EDT
Withdrawn Not applicable Interventional

Stem Cells vs. Steroids for Discogenic Back Pain

NCT04735185
View directory record Official record
Conditions
Chronic Low Back Pain, Degenerative Disc Disease
Interventions
Autologous stem cells, Corticosteroid, Local anesthetic
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 10, 2026, 10:48 PM EDT
Terminated Phase 1 Interventional Results available

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

NCT04397796
View directory record Official record
Conditions
COVID
Interventions
BM-Allo.MSC, Placebo
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lynwood, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 10, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft

NCT01413061
View directory record Official record
Conditions
Degenerative Osteoarthritis, Post-traumatic; Arthrosis, Rheumatoid Arthritis & Other Inflammatory Polyarthropathies, Rheumatoid Arthritis of Subtalar Joint
Interventions
Subtalar Arthrodesis
Procedure
Lead sponsor
AlloSource
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
5
States / cities
Baltimore, Maryland • Grand Rapids, Michigan • Edina, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 10, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT05705024
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Mesenchymal Stromal Cells, Control Solution
Biological · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 10, 2026, 10:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ExoFlo for the Treatment of Perianal Fistulas

NCT05836883
View directory record Official record
Conditions
Perianal Fistula, Crohn's Disease
Interventions
ExoFlo, Local injection of normal saline
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 10:48 PM EDT